The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...